RT Journal Article
SR Electronic
T1 Variable Effects of 3 Different Chondroitin Sulfate Compounds on Human Osteoarthritic Cartilage/Chondrocytes: Relevance of Purity and Production Process
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.090696
DO 10.3899/jrheum.090696
A1 Steeve Kwan Tat
A1 Jean-Pierre Pelletier
A1 François Mineau
A1 Nicolas Duval
A1 Johanne Martel-Pelletier
YR 2010
UL http://www.jrheum.org/content/early/2010/01/27/jrheum.090696.abstract
AB Objective During osteoarthritis (OA), the altered metabolism of cartilage involves proinflammatory factors and matrix metalloprotease (MMP) activity. Studies showed that chondroitin sulfate (CS) may exert a positive effect on the cartilage. Because of differences in CS in terms of purity and the production/purification process, we compared the effects of 3 different types of CS on human OA cartilage. Methods Three types of CS were tested: CS1 (porcine, purity 90.4%), CS2 (bovine, purity 96.2%), and CS3 (bovine, purity 99.9%). Treatment with CS at 200 and 1000 µg/ml was performed on human OA cartilage explants in the presence/absence of interleukin 1ß (IL-1ß), and the protein modulations of factors including prostaglandin E2 (PGE2), IL-6, and MMP-1 measured by ELISA. The CS effect on the expression of collagen type II was also investigated on OA chondrocytes using quantitative polymerase chain reaction. Results In the presence of IL-1ß, CS2 at 1000 µg/ml significantly inhibited IL-6 and PGE2 production, and CS3 at 200 µg/ml markedly reduced the level of IL-6. CS1 was much less efficient at reducing the catabolic markers and in the absence of IL-1ß, it significantly increased IL-6 and MMP-1. IL-1ß significantly inhibited the gene expression level of collagen type II; only CS3 was able to limit this inhibition. CS1, in the presence or absence of IL-1ß, further markedly decreased collagen type II expression. Conclusion Our data indicate that among the 3 tested CS, CS1 increased production of some catabolic pathways and inhibited the gene expression level of collagen type II. Our study provides new information in the context of prescribing CS for alleviating OA symptoms, as the purity and/or production/purification of the CS compound could orient the current OA disease process toward increased catabolic pathways.